Tuesday Aug 11th, 11 AM EST: Live AI Dream Session: Blueprint your enterprise AI strategy with the DARWIN Framework. Reserve your Spot Claim Free Seat

Reserve your Spot

LLM Infrastructure Solutions: Choosing the Right Setup for Model Size, Cost, and Compliance

Many teams approach LLM infrastructure solutions the way someone buys a vehicle before knowing the commute  selecting a general-purpose setup before the real workload arrives with requirements nobody planned for.
A general-purpose setup gets provisioned, budgets get signed off, and then the real workload arrives carrying requirements nobody planned for: a model too large for the reserved memory, latency targets the serving layer cannot meet, or regulated data that legally cannot travel to the chosen endpoint. What follows is either idle capacity quietly burning money or a rushed rebuild a few months later.
This is why LLM infrastructure solutions are not a single blueprint. The right setup depends on how large the model is, how fast and how often it needs to respond, what it costs to run at volume, and where the underlying data is permitted to sit.
Getting those LLM infrastructure requirements straight before committing to hardware is the difference between a setup that scales and one that has to be torn out and rebuilt within a year.

Key Takeaways

Why LLM Infrastructure Solutions Are Never One-Size-Fits-All

The clearest reason is memory. Model weights must sit in fast memory to serve responses at a usable speed, and that requirement scales directly with the number of parameters. Stored in half-precision (FP16, or 16-bit floating-point), each parameter takes roughly two bytes. A 70-billion-parameter model therefore needs about 140 gigabytes of video memory (VRAM) just to hold its weights. That already exceeds a single 80 GB accelerator and forces the model across at least two high-end graphics processing units (GPUs), or around six consumer-grade cards.1 A two-billion-parameter model, by contrast, fits comfortably on one modest GPU.
That single fact reshapes everything downstream. A small model can run on a single card, sometimes even on a central processing unit (CPU), while a frontier-scale model may need a coordinated cluster with high-speed interconnects between chips.
The LLM infrastructure requirements for a lightweight classification assistant and for a 500-billion-parameter reasoning system are not different by degree; they are different in kind. Provisioning both from the same template guarantees waste at one end and failure at the other.
Quantization changes the arithmetic but does not remove the decision. Compressing weights to lower precision can shrink that same 70B model to a fraction of its footprint, letting it run on far less hardware at some cost to output quality. Whether that trade is acceptable depends entirely on the use case, which is exactly why the sizing conversation has to happen before anything is bought.

The Four Variables That Define LLM Infrastructure Requirements

Defining LLM infrastructure requirements starts with four variables : model size, throughput and latency, inference cost, and compliance. Model size is the first lever. Three others matter just as much.

Throughput and latency

A batch job that summarizes documents overnight tolerates slow responses and heavy batching. A customer-facing assistant expected to reply in under a second does not.
The same model can call for very different serving setups depending on how many concurrent requests it fields and how quickly each one has to return. Under-provision here and the system buckles at peak load; over-provision and expensive accelerators sit idle most of the day.

Cost, which moves faster than most budgets assume

For a model of equivalent performance, the price of running inference has been falling by roughly 10x per year, dropping from about $60 per million tokens in 2021 to near $0.06 for a comparable-quality model three years later.
That trajectory rewards flexibility and punishes lock-in. A setup optimized around today’s model at today’s prices can turn uneconomical within a year, and a rigid, single-vendor footprint often costs more over its life than a design built to swap models as cheaper, better options appear.

Compliance

For regulated organizations, this fourth lever frequently overrides the other three. Where data is allowed to be processed can rule out otherwise sensible options entirely, which is worth treating on its own terms.

What Does an LLM Infrastructure Stack Include?

It helps to see the whole picture, because the LLM infrastructure stack is far more than the GPUs everyone talks about. It runs from the compute and serving layer that hosts the model, through an orchestration layer that routes and scales requests, to the data layer that supplies the model with current, trustworthy context, and finally a security and governance layer that controls who can see what.
In a retrieval-augmented setup, the data layer does as much to determine answer quality as the model does – a trade-off explored in depth in RAG vs. Fine-Tuning: How Enterprise Teams Should Actually Decide.
Teams that fixate on the compute layer tend to meet the rest of the stack the hard way. A pilot works cleanly in a demo, then stalls the moment it hits real data volumes, real access rules, and real audit expectations. The compute was never the part most likely to break.

How Compliance Requirements Shape LLM Infrastructure Solutions for Regulated Industries

For pharmaceutical and life sciences organizations, healthcare systems, financial firms, and public-sector agencies, the question of where data can go often settles the infrastructure question before performance enters the conversation. Regulated data cannot simply be pointed at whatever endpoint is cheapest.
Protected health information under the Health Insurance Portability and Accountability Act (HIPAA), records governed by 21 CFR Part 11, and systems under the Federal Information Security Management Act (FISMA) each constrain where processing may happen and who may access it.
The concern is widespread, not niche. In Deloitte’s 2026 State of AI in the Enterprise survey, data privacy and security ranked as the most cited AI risk, named by 73% of the leaders polled.
Once data residency and sovereignty enter the picture, a public interface sitting in the wrong jurisdiction stops being an option, and the field narrows to controlled cloud, on-premises, hybrid, or air-gapped setups. Retrofitting those controls after a system is live is almost always slower and costlier than designing for them from the outset – a principle at the core of AI governance for regulated industries.

Why the Data Layer Determines LLM Infrastructure Success

Compute gets the headlines, but the data foundation quietly decides the outcome. A perfectly sized cluster still returns unreliable output if the pipelines feeding it are fragmented, stale, or impossible to trace. In regulated settings, every input and output usually has to carry a lineage a reviewer can follow, which is a data-engineering problem long before it is a hardware one. This is the layer where most infrastructure plans succeed or come apart.

How Intuceo Delivers LLM Infrastructure Solutions for Regulated Enterprises

This is the part of an infrastructure solution that Intuceo is set up to handle. Its DataOps and Engineering practice concentrates on the layer that determines whether an LLM setup holds up in production: hardened ingestion and transformation pipelines with automated quality testing, full data lineage for GxP, HIPAA, and federal audits, and secure infrastructure configured across cloud, on-premises, or hybrid environments with controls such as virtual private cloud (VPC) isolation and customer-managed encryption keys.
Rather than installing a fixed toolset, Intuceo works as a services partner, bringing accelerators drawn from prior regulated engagements to speed up deployment and configuring the pipeline to the constraints an organization already operates under. The compute can be right-sized later; the data foundation has to be sound first.
That foundation still rests on getting the hardware decision right – the exact problem the DARWIN Infrastructure planning session addresses by working through the LLM infrastructure solutions trade-off for your specific model, budget, and regulatory reality.
The session uses the Infrastructure dimension of the DARWIN planning framework to work through the real cost and performance trade-offs, from GPU versus CPU choices to sizing questions as concrete as whether a workload needs a dozen servers for a 500-billion-parameter model or a single GPU for a two-billion-parameter one.
It is built for the data, engineering, compliance, and executive leaders who own those calls, and it answers the question most infrastructure discussions skip: how to choose a setup that fits the model, the budget, and the regulatory reality at the same time.

Size your setup before you commit to it

Join the Intuceo AI Dream Session to work through the cost, performance, and compliance trade-offs behind your LLM infrastructure, with worked examples from regulated deployments.

Frequently Asked Questions

Sound LLM infrastructure requirements planning weighs four factors together: model size, which sets memory and GPU count; throughput and latency, which shape the serving setup; running cost at volume; and compliance, which governs where data can be processed  Sound LLM infrastructure requirements planning weighs all four together rather than optimizing for one and discovering the others later.
No. Small models can run on a single modest GPU or even a CPU, while large models need multiple high-end accelerators working together. Matching the hardware to the model, instead of defaulting to the largest option, is often where the biggest savings sit.
A complete LLM infrastructure stack includes the compute and serving layer, an orchestration layer for routing and scaling, a data layer that supplies context and retrieval, and a security and governance layer for access control and auditability. The data and governance layers are where regulated deployments most often succeed or stall.
In regulated industries, compliance can decide the infrastructure before performance is discussed. Rules such as HIPAA, 21 CFR Part 11, and FISMA limit where data may be processed, which pushes many organizations toward controlled cloud, on-premises, hybrid, or air-gapped setups rather than a public interface.
It depends on the data and the workload. Cloud offers elasticity, on-premises offers control, and hybrid balances the two. For sensitive data with residency or sovereignty constraints, the deciding factor is usually where processing is legally allowed to happen, not raw performance.

Best AI Analytics Companies in Florida for Pharma and Life Sciences (2026)

Teams searching for an analytics partner in Florida usually have a specific problem in hand. Trial enrollment is behind. Adverse event review is still manual. Research data sits across systems nobody can search. The useful question for any team evaluating pharma AI analytics companies in Florida is not who claims to do artificial intelligence (AI), but which nearby firms have actually shipped inside a regulated environment.
There are more credible answers than a few years ago. Florida’s bioscience workforce reached 116,635 employees across 9,481 companies in 2023, an 18.7% increase since 2019 and faster than national life sciences employment growth[1]. A base that size now sustains its own AI and analytics supply chain. The guide below covers how to evaluate a partner and the best AI analytics companies in Florida for pharma and life sciences teams heading into 2026.

Key Takeaways

How AI is used in pharma data analytics in 2026

The regulatory record is a useful proxy for how far this has traveled. FDA’s Center for Drug Evaluation and Research reports more than 500 drug submissions containing AI components between 2016 and 2023, spanning non-clinical, clinical, postmarketing, and manufacturing phases[2]. In January 2026, the FDA and the European Medicines Agency published ten joint guiding principles for good AI practice in drug development, an unusual signal of how quickly the two agencies expect sponsors to standardize.
Operationally, this is narrower than the marketing suggests. Most current pharma data analytics in Florida falls into four buckets: knowledge retrieval across research documents and regulatory filings; cohort identification and site feasibility work in AI for clinical trials; automated classification and triage in pharmacovigilance; and yield, defect and release analytics in manufacturing. Discovery-stage generative chemistry gets the headlines; the recurring budget sits in those four areas.

How to Evaluate Pharma AI Analytics Companies: 5 Checks That Separate Specialists from Generalists

Evaluation usually stalls on one question: how do you separate a competent analytics consultancy from one that has shipped in a validated environment? Five checks do most of the work when assessing life sciences AI vendors in 2026.

The Best Pharma AI Analytics Companies in Florida (2026)

These five were selected on verifiable life sciences delivery, substantive Florida presence, and distinct capability, so the list is comparative rather than five versions of the same offer. They are not ranked against each other.

1. Intuceo - Jacksonville

Custom AI and data engineering for regulated life sciences | PhD-led delivery
Intuceo is the option on this list built for sponsors who need engineering rather than access to somebody else’s dataset. The firm works across the pharma value chain: research knowledge retrieval, generative AI patient matching for trial enrollment, site performance analytics, pharmacovigilance classification, and quality and manufacturing analytics in Good Practice (GxP) regulated environments. Named pharma and medtech engagements include Janssen Pharma, Ferring Pharma, and Bausch & Lomb.
Three things separate it from a general analytics consultancy. First, delivery is PhD-led, with a Board of Science that reviews model design and scientific validity rather than leaving that judgement to a delivery manager. Second, Intuceo brings named accelerators to compress build time: Intuceo-Ax™ for augmented analytics, Intuceo-Ix™ for neural search across fragmented research repositories, and Intuceo-Dx™ for document and vision intelligence. These are starting points drawn from prior regulated engagements, not licensed software, and are adapted to the sponsor’s validation and data estate.
Third, and most relevant to anyone who has been through an inspection, Intuceo builds explainable AI into adverse event work. The classification and the evidence-based rationale supporting it are generated together, which is the difference between a model that saves reviewer hours and one that creates them. Its iPDLC™ delivery framework carries the quality gates, traceability, and documentation that FDA 21 CFR Part 11, HIPAA, and GxP reviewers expect.
The firm is headquartered in Jacksonville, with a certified engineering bench and a Florida client history across research and healthcare. That buys same-time-zone working, on-site workshops, and accountability that survives the first difficult quarter.
Best for: sponsors and contract research organizations (CROs) needing custom, validated AI built across research, clinical and quality workflows.

2. Aster Insights - Tampa

Oncology real-world data and clinical intelligence
Aster Insights, a subsidiary of Moffitt Cancer Center[4], leads the Oncology Research Information Exchange Network (ORIEN), a consortium of leading US cancer centers. Its Avatar dataset pairs clinical, molecular, and digital pathology imaging data, and ORIEN members participate in the Total Cancer Care study, which has accrued over 400,000 patients[5]. For biopharma running oncology programs, that lifetime-consented, multimodal cohort supports external control arms, biomarker research and translational work that is slow to assemble independently.
Best for: oncology sponsors needing consented multimodal real-world evidence and academic research partnerships.

3. NeoGenomics - Fort Myers

Precision oncology testing, informatics and biopharma services
NeoGenomics runs laboratories accredited by the College of American Pathologists and certified under the Clinical Laboratory Improvement Amendments from a Fort Myers base, serving pharma clients through its biopharma services group. On the data side, it makes over 2.5 million digital pathology images available for machine learning model development and training, paired with patient and clinical history, and identifies trial-eligible patients from a pool of more than two million profiles[6]. It is the closest thing in Florida to an integrated route from assay to algorithm-ready imaging corpus.
Best for: teams building imaging-based models or needing biomarker testing and trial recruitment under one contract.

4. Intego Clinical - Orlando

Biometrics CRO: biostatistics, statistical programming, data management
Intego Clinical is a biometrics CRO headquartered in Orlando, with delivery centers in Central Florida, Poland, Ukraine, and Costa Rica. Its work is the unglamorous foundation everything else depends on: datasets conforming to Clinical Data Interchange Standards Consortium models, submission-ready statistical output, and clinical data management across ophthalmology, oncology, neurology and virology[7]. Team continuity is a stated strength, with 85% of staff bringing more than five years of experience[8], which matters on studies that outlast most vendor relationships.
Best for: sponsors outsourcing trial biometrics and needing standards-compliant datasets for submission.

5. ModMed - Boca Raton

Specialty real-world data for evidence generation and outcomes research
Best known as a specialty practice technology firm, ModMed’s Boca Raton real-world data group is now a serious option for life sciences researchers. Because clinical detail is captured in structured fields at the point of care rather than free text, the datasets arrive analysis-ready. Its dermatology network covers over 98 million patients and 481 million encounters, with a separate ophthalmology network of over 18 million patients[9]. For dermatology and ophthalmology indications specifically, that depth of structured outcome measures is difficult to source elsewhere.
Best for: health economics and outcomes research teams working in dermatology or ophthalmology.

Matching the firm to the stage of work

Treating these five pharma AI analytics companies in Florida as one shortlist is how procurement ends up comparing a data licence against an engineering statement of work. If the gap is evidence, Aster Insights, NeoGenomics and ModMed supply data assets in oncology, imaging and specialty care. If the gap is trial execution, Intego Clinical covers biometrics. If internal systems cannot support life sciences AI analytics at all, because research knowledge sits in unsearchable repositories or adverse event review is still manual, the requirement is engineering, and that points to Intuceo.
One caution for vendor calls: a firm that answers every capability question affirmatively is describing a sales position, not a delivery record. Ask for the regulated engagement closest to yours, and who on their team wrote its validation documentation.

Scoping a regulated AI program in Florida?

Intuceo’s PhD-led team works with pharma, biotech, and medtech sponsors on clinical trial matching, research knowledge retrieval, adverse event classification, and GxP manufacturing analytics. Bring the workflow that is stuck, and we will map what a validated build requires.

Frequently Asked Questions

The central requirement is model credibility for a defined context of use. FDA’s draft guidance on AI supporting regulatory decision-making sets out a risk-based credibility assessment framework covering nonclinical, clinical, postmarketing and manufacturing uses[3]. Alongside it, GxP expectations and 21 CFR Part 11 govern electronic records and signatures, meaning audit trails, access controls, versioning and documented change management apply to models as they do to any other regulated system. Where a model output informs a safety or efficacy conclusion, the reasoning behind that output has to be reconstructable, not just the result.
Four uses are well established. Cohort identification screens structured and unstructured records against inclusion and exclusion criteria far faster than manual chart review. Site feasibility modeling uses historical enrollment patterns to flag sites likely to underperform before contracts are signed. Risk-based monitoring surfaces anomalous data patterns across sites during conduct rather than at database lock. Natural language processing extracts endpoints and adverse events from narrative fields. In each case, the model narrows the field for human reviewers; it does not replace the statistical analysis plan or the medical monitor.
Intuceo has delivered engagements for Janssen Pharma, Ferring Pharma and Bausch & Lomb, spanning research knowledge retrieval, clinical trial patient matching, adverse event detection and manufacturing quality analytics. Work is delivered under the iPDLC™ framework with PhD-led scientific review, and draws on accelerators including Intuceo-Ax™ for augmented analytics, Intuceo-Ix™ for neural search across research repositories, and Intuceo-Dx™ for document and vision intelligence. Engagements are structured as fixed-bid statements of work or embedded teams depending on whether the deliverable is defined or the goal is building internal capability.
Technical skill is broadly comparable. The difference is what the team assumes without being told. A specialist knows that a model touching a submission needs a credibility argument, that adverse event classification requires documented rationale rather than a probability score, and that changing a feature set mid-study has consequences for the statistical analysis plan. A generalist learns these things during your engagement, on your timeline, at your cost. The gap shows up as rework and inspection risk rather than as a lower day rate.

What Are the Best AI Development Lifecycle Frameworks for Regulated Analytics?

An estimated 80% of enterprise AI projects fail to deliver their intended business value, according to RAND Corporation’s 2025 analysis. In regulated industries like life sciences and healthcare, the stakes are even higher. A flawed model does not just waste budget; it can trigger compliance violations, endanger patient safety, or invalidate years of clinical research.
The core issue goes beyond the algorithm; it is the absence of a structured AI development lifecycle framework that governs how models are built, validated, monitored, and retired. Traditional SDLC processes assume deterministic outputs. AI systems produce probabilistic results that require fundamentally different governance, from data provenance to drift detection to explainability. For life sciences organizations operating under FDA 21 CFR Part 11, HIPAA, and GxP, choosing the right AI lifecycle framework is foundational.

Key Requirements When Evaluating an AI Development Lifecycle Framework for Regulated Analytics

Before comparing specific frameworks, it helps to define what “regulated-ready” demands. These are the non-negotiable considerations for any AI lifecycle framework used in life sciences or healthcare analytics.
Requirement Why It Matters in Regulated Analytics
Audit-ready documentation FDA and GxP audits require immutable records of data lineage, model decisions, and validation steps at every stage.
Explainability (XAI) Regulators and clinicians need to understand why a model made a specific prediction, particularly in pharmacovigilance and clinical trial matching.
Hallucination and drift detection LLM outputs and ML predictions degrade over time. Production AI monitoring must detect statistical drift, output toxicity, and hallucination before they affect decisions.
Model version control Every model iteration, training dataset, and hyperparameter change must be versioned and traceable for 21 CFR Part 11 compliance.
Human-in-the-loop validation Non-deterministic AI outputs require expert review gates, especially where patient safety or regulatory submissions are involved.
Cross-regulation alignment A single framework should map to multiple mandates: HIPAA, FISMA, NIST 800-53, GxP, and GDPR simultaneously.
With these criteria established, which AI development lifecycle frameworks meet these standards?

Top AI Development Lifecycle Frameworks for Regulated Analytics: A Comparative View

1. NIST AI Risk Management Framework (AI RMF 1.0)

Released in January 2023, the NIST AI RMF has become the de facto AI governance standard in the United States, organized around four functions: Govern, Map, Measure, and Manage. NIST expanded it in July 2024 with a Generative AI Profile (AI 600-1) adding over 200 actions for LLM-specific risks.FDA and other sector regulators increasingly reference its principles.
Strengths
Limitations
Best for: Enterprises needing regulatory alignment across multiple mandates (HIPAA, FISMA, GxP) without being locked into a single vendor ecosystem.

2. CRISP-DM (Cross Industry Standard Process for Data Mining)

CRISP-DM has been the most widely adopted data science methodology since 1999. Its six-phase cycle (Business Understanding, Data Understanding, Data Preparation, Modeling, Evaluation, Deployment) provides a structured, iterative approach. Comparative research found CRISP-DM showed the highest alignment with ISO/IEC 29110 standards among the frameworks analyzed.
Strengths
Limitations
Best for: Teams needing a proven analytical workflow structure, supplemented with separate governance and MLOps layers for regulated environments.

3. Microsoft TDSP (Team Data Science Process)

TDSP extends CRISP-DM with a five-stage lifecycle and adds standardized deliverables, role definitions, and collaboration templates. Its customer acceptance phase and prescribed documentation make it more enterprise-ready than CRISP-DM.
Strengths
Limitations
Best for: Organizations already operating within the Azure/Microsoft ecosystem that need standardized data science workflows across large teams.

4. MLOps (ML Operations Lifecycle)

MLOps applies DevOps principles (CI/CD, infrastructure-as-code, automated testing) to machine learning. It emphasizes continuous integration, delivery, and monitoring of ML models in production, extending traditional frameworks with automated testing, version control, and drift detection.
Strengths
Limitations
Best for: Technically mature organizations that need to scale production AI monitoring and model governance across multiple deployed models.

5. iPDLC™ (Intelligent Product Development Lifecycle) by Intuceo

Where the frameworks above address parts of the AI lifecycle, Intuceo’s proprietary iPDLC™ was purpose-built for regulated, high-stakes environments. It integrates AI-augmented engineering with PhD-led quality gates at every milestone, governing the full lifecycle from intelligent discovery through hardened production to continuous governance.
iPDLC operates across five pillars: Intelligent Discovery and Requirement Synthesis, Architectural Blueprinting, Logic-Driven Test Engineering, Hardened Production Engineering, and Observability with Continuous Governance. Each pillar includes a mandatory Human-in-the-Loop checkpoint validated by Intuceo’s Board of Science, ensuring mathematical soundness and audit readiness.
Strengths
Limitations
Best for: Life sciences, healthcare, and public sector organizations that need a compliance-first AI lifecycle framework with built-in scientific oversight and production-grade reliability.

Framework Comparison at a Glance

Capability NIST AI RMF CRISP-DM TDSP MLOps iPDLC™
Regulatory compliance (native) Partial No No No Yes
Audit-ready documentation Guidance only No Templates Tool-dependent Automated
Explainability / XAI Recommended No No Add-on Built-in (PhD-led)
Drift detection & monitoring Recommended No No Yes Yes (self-healing)
LLM / GenAI evaluation Yes (AI 600-1) No No Emerging Yes
Human-in-the-loop gates Recommended Informal Customer acceptance Optional Mandatory (every pillar)
Vendor lock-in None None Microsoft Tool-dependent Cloud-agnostic

Need a Compliance-First AI Lifecycle for Life Sciences?

Intuceo’s iPDLC™ framework delivers production-grade AI with PhD-led oversight, automated audit trails, and native compliance for 21 CFR Part 11, HIPAA, and GxP environments. Reduce implementation timelines by up to 40% without compromising scientific rigor.

Frequently Asked Questions

A traditional SDLC assumes deterministic software outputs: identical inputs produce identical results. An AI development lifecycle must account for probabilistic outputs, continuous model retraining, data drift, and ongoing validation after deployment. Regulated environments add further layers of documentation, explainability, and version control that standard SDLC processes do not address.
Primary challenges include maintaining audit-ready documentation across model iterations, ensuring explainability for clinical reviewers, detecting drift and hallucinations in production, and aligning a single AI governance framework with overlapping mandates (HIPAA, GxP, 21 CFR Part 11, GDPR). Gartner predicts 60% of AI projects lacking AI-ready data will be abandoned through 2026.
Validation requires statistical testing, human-in-the-loop expert review, automated regression benchmarks, and continuous drift monitoring. In regulated analytics, every validation step must produce an immutable record. NIST AI RMF recommends ongoing measurement across trustworthiness attributes including reliability, safety, fairness, and explainability.
Evaluation starts with baseline benchmarks during development, followed by automated production monitoring. Drift detection compares statistical distributions of inputs and outputs over time. Hallucination evaluation uses ground-truth comparison and retrieval-augmented verification. Toxicity is measured through classifier-based filters and human review. NIST’s Generative AI Profile (AI 600-1) provides over 200 specific actions for managing these LLM risks.
For life sciences, a combination approach works well: NIST AI RMF for governance structure, MLOps tooling for production monitoring, and a compliance-native methodology like iPDLC™ that embeds regulatory checkpoints into every stage. No single open framework currently covers the full spectrum from discovery through governed production in regulated environments.